Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses.

Front Immunol · 2025 · PMC12672258 · PMID 41346586

Europe PMC DOI

hedged sentences

0.0826

closest p · 1.7× alpha

0.0826

boldest claim

The sentences

near-significantp=.0826so close (0.05 < p ≤ 0.1)

Natalizumab-treated pwMS showed a near-significant reduction in CD4+ AIM+ cells at 5–6 months post-vaccination compared to the previous time point (p=.0826) but, following booster dose, the increased proportion of these cells was comparable to that seen following the initial vaccination (p=.0378) ( Figure 4D ).

also in 1,650 other papers

did not reach statistical significanceno p-value reported

This correlation was present at 5–6 months post-vaccine as well but did not reach statistical significance.

also in 75,278 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.